These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1596 related articles for article (PubMed ID: 19629070)

  • 1. Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
    Engelman JA
    Nat Rev Cancer; 2009 Aug; 9(8):550-62. PubMed ID: 19629070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dermatological implications of the PI3K pathway].
    Dereure O
    Ann Dermatol Venereol; 2015 Oct; 142(10):622-3. PubMed ID: 26001484
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of PI3K inhibitors: lessons learned from early clinical trials.
    Rodon J; Dienstmann R; Serra V; Tabernero J
    Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and challenges associated with targeting mTOR for cancer therapy.
    Dowling RJ; Pollak M; Sonenberg N
    BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.
    Westin JR
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):335-42. PubMed ID: 24650973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma.
    King D; Yeomanson D; Bryant HE
    J Pediatr Hematol Oncol; 2015 May; 37(4):245-51. PubMed ID: 25811750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relation between PI3K/AKT signalling pathway and cancer.
    Noorolyai S; Shajari N; Baghbani E; Sadreddini S; Baradaran B
    Gene; 2019 May; 698():120-128. PubMed ID: 30849534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role and therapeutic implications of PI3K signaling pathway in cancer.
    Leiphrakpam PD; Chowdhury S; Wang J; Black JD; Are C
    J Surg Oncol; 2021 Jan; 123(1):39-41. PubMed ID: 33179260
    [No Abstract]   [Full Text] [Related]  

  • 10. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
    Wu P; Hu YZ
    Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.
    Sathe A; Nawroth R
    Methods Mol Biol; 2018; 1655():335-350. PubMed ID: 28889395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current development of mTOR inhibitors as anticancer agents.
    Faivre S; Kroemer G; Raymond E
    Nat Rev Drug Discov; 2006 Aug; 5(8):671-88. PubMed ID: 16883305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q; Lui VW; Yeo W
    Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
    Brenner AK; Andersson Tvedt TH; Bruserud Ø
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PI3K Signaling in Combination Cancer Therapy.
    Pons-Tostivint E; Thibault B; Guillermet-Guibert J
    Trends Cancer; 2017 Jun; 3(6):454-469. PubMed ID: 28718419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.